by 
Nucleic Acid Aptamers Market Key Takeaways
- In terms of revenue, the global nucleic acid aptamers market was valued at USD 257.93 million in 2024.
- It is projected to reach USD 1,267.63 million by 2034.
- The market is expected to grow at a CAGR of 17.26% from 2025 to 2034.
- North America dominated the nucleic acid aptamers market with the largest share of 39% in 2024.
- Asia Pacific is expected to grow at the fastest CAGR from 2025 to 2034.
- By type, the DNA aptamers segment held the highest market share of 45% in 2024.
- By type, the RNA aptamers segment will expand at a significant CAGR between 2025 and 2034.
- By application, the therapeutics segment contributed the biggest market share of 28% in 2024.
- By application, the diagnostics segment will expand at the highest CAGR between 2025 and 2034.
- By synthesis method, the SELEX (systematic evolution of ligands by exponential enrichment) segment led the market, under which the conventional SELEX segment held a significant share as a sub-segment in 2024.
- By synthesis method, the non-SELEX-based methods segment will grow at a significant CAGR between 2025 and 2034.
- By delivery method, the conjugated delivery segment captured the major market share of 41% in 2024.
- By delivery method, the carrier-mediated delivery segment will grow at the highest CAGR between 2025 and 2034.
- By end-user, the pharmaceutical & biotech companies segment generated the major market share of 36% in 2024.
- By end-user, the contract research organizations (CROs) segment will expand at a significant CAGR between 2025 and 2034.
Impact of AI on the Nucleic Acid Aptamers Market
Artificial intelligence is revolutionizing the nucleic acid aptamers market by significantly enhancing discovery, design, and development processes. AI-driven tools are accelerating aptamer discovery by analyzing vast datasets from high-throughput sequencing and optimizing aptamer sequences for improved stability, specificity, and binding affinity. These advancements are particularly valuable in applications such as therapeutics, diagnostics, and biosensing, where performance and precision are critical.
AI-powered in silico modeling is streamlining the design and optimization of aptamers, reducing experimental workloads while enhancing structural efficiency. Machine learning algorithms are also enabling more targeted and personalized approaches in molecular research and drug development.
A major breakthrough came in December 2024, when the National Institutes of Health (NIH) introduced a study featuring DeepAptamer, a deep learning-based computational tool. This technology demonstrated the ability to identify high-affinity aptamers from the early rounds of the SELEX process. By predicting functional aptamer sequences at initial stages, DeepAptamer reduces reliance on extended selection rounds, dramatically shortening the time and cost involved in aptamer development.
Market Overview
The nucleic acid aptamers market encompasses the global landscape of research, development, manufacturing, and commercialization of short, single-stranded DNA or RNA molecules known as aptamers. These molecules are engineered to bind selectively and with high affinity to specific target molecules, serving as effective alternatives to antibodies. Due to their versatility, aptamers are increasingly used across a wide range of applications including therapeutics, diagnostics, targeted drug delivery, biomarker discovery, biosensing, and molecular research.
Aptamers offer several advantages over traditional antibodies, such as greater stability, high specificity, ease of chemical synthesis, and low immunogenicity. These features make them particularly attractive for biomedical and pharmaceutical innovations.
Market growth is being driven by rising demand for precision therapies and personalized medicine, especially in the context of chronic diseases. Additionally, expanding investment in R&D activities, particularly in biotechnology and pharmaceutical sectors, is fueling innovation in aptamer-based technologies and applications. As the need for highly specific, cost-effective molecular targeting solutions continues to grow, nucleic acid aptamers are expected to play an increasingly vital role in the future of diagnostics and therapeutics.
Key Trends in the Nucleic Acid Aptamers Market
- Rising Prevalence of Chronic Diseases: The global increase in chronic conditions such as cancer, cardiovascular diseases, and autoimmune disorders is fueling demand for aptamer-based diagnostics and therapeutics due to their high specificity and sensitivity.
- Growing Demand for Targeted Therapies: As precision medicine gains momentum, the need for highly specific targeting agents is rising. Aptamers are emerging as a promising alternative to traditional antibodies for targeted therapy, owing to their customizable and low-immunogenic nature.
- Advancements in Biotechnology: Innovations in biotechnology—particularly in aptamer selection, chemical modification, and stabilization—are improving the performance and reliability of aptamers, encouraging their broader adoption in both diagnostics and drug development.
- Surge in Personalized Medicine: The push toward individualized treatment strategies is increasing the need for precise diagnostic tools. Aptamers, with their tunable binding capabilities, are well-suited for applications in personalized medicine and companion diagnostics.
- Expanding Application Versatility: Ongoing research is uncovering new uses for aptamers across various domains, including biosensing, biomarker detection, and high-throughput drug screening. Their ability to bind with high affinity to a wide range of targets is expanding their utility across both clinical and research settings.
Market Opportunity
Technological Advances in Aptamer Development
The nucleic acid aptamers market is poised for substantial growth, driven by ongoing technological innovations that are streamlining and enhancing the aptamer development process. Advancements in SELEX (Systematic Evolution of Ligands by Exponential Enrichment) are significantly improving the selection precision and stability of aptamers, thereby facilitating their wider adoption in both diagnostics and therapeutic applications.
Innovations in delivery systems, such as nanoparticle-based platforms and conjugation techniques, are enabling more efficient and targeted delivery of aptamers, reducing off-target effects and improving treatment efficacy. These developments are particularly promising in fields like oncology, where precision targeting is essential.
Additionally, improvements in amplification methods, high-throughput sequencing technologies, and oligonucleotide library design are enhancing the speed, scalability, and cost-effectiveness of aptamer development. As a result, these technologies are making aptamer-based solutions more accessible to research institutions, pharmaceutical companies, and healthcare systems worldwide.
Nucleic Acid Aptamers Market Key Players
- SomaLogic Inc.
- Aptamer Group PLC
- NOXXON Pharma AG
- Base Pair Biotechnologies Inc.
- Aptamer Sciences Inc.
- AM Biotechnologies LLC
- NeoVentures Biotechnology Inc.
- TriLink BioTechnologies LLC
- Aptus Biotech S.L.
- Aptagen LLC
- Vivonics Inc.
- Aptamer Solutions Ltd.
- AuramerBio Ltd.
- Bio-Techne Corporation
- Novaptech
- IBA GmbH
- ATDBio Ltd.
- Raptamer Discovery Group
- LC Sciences LLC
- Integrated DNA Technologies (IDT)
Recent Developments
- In June 2025, ACS publications reported achieving a detection limit of 60 and 70 nM in spiked artificial saliva by developing a biosensor using two MPD aptamers. This biosensor also exhibits a linear detection range from 100 to 1000 nM. (Source: https://pubs.acs.org)
- In April 2025, the International Society on Aptamers hosted the 12th annual aptamers conference in Oxford, UK, as a ‘virtual-in-person’ hybrid mode. This conference brings emerging aptamer researchers and students to submit their abstracts for oral and poster presentations.
- In May 2025, Ajinomoto Co., Inc. collaborated with RIBOMIC Inc., a drug discovery startup focused on the development and production of aptamer pharmaceuticals, to develop technology to control the pharmacokinetics of nucleic acid aptamers by using the antibody-drug conjugated (ADC) manufacturing technology “AJICAP”. The innovation has resulted in extending the half-life of a nucleic acid aptamer conjugate.
